Dexmedetomidine hydrochloride for injection, USP recalled over out-of-specification test result
A test result for dexmedetomidine hydrochloride for injection, USP was out of specification, which the notice lists as a product quality issue.
What to do
Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns. Contact the recalling firm if you have any questions about the recall.
Recall details
- Product
- DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION, USP
- Hazard
- Product quality
- Class or risk level
- Type II
- Notice last updated
- November 7, 2025
- Listed on Recalled Today
- November 7, 2025
Recalled Today dates each recall from the day it first appeared in the official data.
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from Health Canada.
DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION, USP: Out of Specification Test Result
- Product
- DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION, USP
- Issue
- Product quality
- What you should do
- Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.
- Recall class
- Type II
- Category
- Drugs
- Organization
- Drugs and health products
Contains information licensed under the Open Government Licence – Canada. Open Government Licence
Recalled Today is independent and is not an official government page.
Related recalls
Locametz powder for solution, kit recalled over unknown impurity outside limits
The notice says Locametz powder for solution, kit is out of specification because of an unknown impurity, which it lists as a product quality issue.
Cisatracurium besylate injection multidose recalled over degradation product that may exceed limit
The level of a degradation product called Benzaldehyde may be out of specification in the affected lots of this product.